Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 761042
Company: SANDOZ
Company: SANDOZ
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
ERELZI | ETANERCEPT-SZZS | 25MG/0.5ML | INJECTABLE; INJECTION | Prescription | None | No | No |
ERELZI | ETANERCEPT-SZZS | 50MG/ML | INJECTABLE; INJECTION | Prescription | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
08/30/2016 | ORIG-1 | Approval | N/A |
Label (PDF)
Letter (PDF) Review Summary Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761042lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/761042Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761042Orig1_toc.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761042Orig1s000SumR.pdf |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
11/10/2022 | SUPPL-18 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761042s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/761042Orig1s018ltr.pdf | |
06/11/2020 | SUPPL-12 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761042s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761042Orig1s012ltr.pdf | |
10/18/2019 | SUPPL-10 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761042s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761042Orig1s010ltr.pdf | |
01/26/2018 | SUPPL-1 | Supplement |
Label (PDF)
Letter (PDF) Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761042s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761042Orig1s001ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761042Orig1s01.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
11/10/2022 | SUPPL-18 | Efficacy-New Patient Population | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761042s018lbl.pdf | |
06/11/2020 | SUPPL-12 | Efficacy-New Patient Population | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761042s012lbl.pdf | |
10/18/2019 | SUPPL-10 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761042s010lbl.pdf | |
01/26/2018 | SUPPL-1 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761042s001lbl.pdf | |
01/26/2018 | SUPPL-1 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761042s001lbl.pdf | |
08/30/2016 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761042lbl.pdf |